Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Prostate Cancer (Jan 2020)

Posted by Matt Breese on Jan 17, 2020

Find me on:

According to our recent payer coverage analysis for prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for prostate cancer treatments shows that under the pharmacy benefit, almost half of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Prostate Cancer-1Q2020Data snapshot as of Q1 2020

Trends: In December 2019, the FDA granted another indication to Xtandi (enzalutamide) for the treatment of men with metastatic castrationsensitive prostate cancer.  

To read the full Reality Check on Prostate Cancer treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing